Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Sponsor

Nohla Therapeutics, Inc. (Industry)

Overall Status

Terminated

CT.gov ID

NCT01701323

Collaborator

National Cancer Institute (NCI) (NIH), Fred Hutchinson Cancer Center (Other)

Enrollment

Locations

Arm

Actual Duration (Months)

3.5

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This pilot clinical trial studies infusion of expanded cord blood hematopoietic progenitor cells following combination chemotherapy in treating younger patients with acute myeloid leukemia that has relapsed or has not responded to treatment. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemotherapy also kills healthy infection-fighting cells, increasing the risk of infection. The infusion of expanded cord blood hematopoietic progenitor cells may be able to replace blood-forming cells that were destroyed by chemotherapy. This cellular therapy may decrease the risk of infection following chemotherapy.

Condition or Disease	Intervention/Treatment	Phase
Acute Leukemia of Ambiguous Lineage Acute Myeloid Leukemia	Biological: Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion Drug: Cytarabine Drug: Filgrastim Drug: Fludarabine Phosphate	Phase 1

Study Design

Study Type:

Interventional

Actual Enrollment :

7 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Chemotherapy (FLAG) in Patients With AML or Acute Leukemia of Ambiguous Lineage

Actual Study Start Date :

Dec 10, 2012

Actual Primary Completion Date :

May 10, 2018

Actual Study Completion Date :

May 10, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment (Ex-vivo expanded cord blood progenitors) Patients receive filgrastim SC or IV on days 1-7, fludarabine phosphate IV QD over 30 minutes on days 2-6, cytarabine IV QD over 4 hours on days 2-6, and ex-vivo expanded cord blood progenitor cells IV over 30 minutes on day 8.	Biological: Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion Given IV Other Names: NLA101 Dilanubicel Drug: Cytarabine Given IV Drug: Filgrastim Given SC or IV Drug: Fludarabine Phosphate Given IV

Arm

Intervention/Treatment

Experimental: Treatment (Ex-vivo expanded cord blood progenitors)

Patients receive filgrastim SC or IV on days 1-7, fludarabine phosphate IV QD over 30 minutes on days 2-6, cytarabine IV QD over 4 hours on days 2-6, and ex-vivo expanded cord blood progenitor cells IV over 30 minutes on day 8.

Biological: Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion

Given IV

Other Names:

NLA101

Dilanubicel

Drug: Cytarabine

Given IV

Drug: Filgrastim

Given SC or IV

Drug: Fludarabine Phosphate

Given IV

Outcome Measures

Primary Outcome Measures

Incidence of NCI CTCAE grade > 3 infusional toxicities [Up to 2 years]
Occurrence of transfusion associated graft versus host disease [Up to 2 years]
Incidence of platelet refractoriness in the presence of alloimmunization as a direct result of ex vivo expanded cord blood product infusion [Up to 2 years]
Incidence of delayed marrow recovery [Up to day 42]
Failure to achieve ANC >= 500 cells/µl by day 42 post treatment with marrow cellularity < 5% and marrow blast count < 5%.
Rate of treatment related mortality [Up to 2 years]

Secondary Outcome Measures

Time to neutrophil recovery [Up to 2 years]
ANC >= 100 cells/ul and 500 cells/ul
In vivo persistence of ex vivo expanded cellular therapy [Up to 2 years]
Assessed by peripheral blood cell sorted deoxyribonucleic acid (DNA) chimerisms of the cluster of differentiation myeloid and lymphoid cell lineages as well as whole marrow chimerisms.
Patient and infused expanded cord blood cells immune interaction [Up to 2 years]
Assessed by performing host-donor studies.
Incidence of NCI CTCAE grade 3 or 4 infections [First 30 days following FLAG administration]
Incidence of NCI CTCAE grade > 3 chemotherapy-related toxicity in the first 30 days following fludarabine phosphate, cytarabine, and filgrastim (FLAG) therapy [First 30 days following FLAG administration]
Rate of complete remission [Up to 2 years]
Leukemia-free survival [Up to 2 years]
Overall survival [Up to 2 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:

6 Months to 30 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients must have a diagnosis of AML or acute leukemia of ambiguous lineage according to World Health Organization (WHO) classification with >= 5% of disease in bone marrow (BM)
Recipients of prior allogeneic hematopoietic stem cell transplantation for AML or acute leukemia of ambiguous lineage are eligible if they do not have graft-versus-host disease (GVHD) or they have quiescent GVHD whether or not they are receiving immunosuppressive therapy
Must have a Lansky or Karnofsky performance status of >= 50; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
Patients must have recovered from the acute toxicity of all prior chemotherapy
The following amounts of time must have elapsed prior to entry on study:
2 weeks from local radiation therapy (XRT)
8 weeks from prior craniospinal or if > 50% of the pelvis has been irradiated
6 weeks must have elapsed if other bone marrow radiation has occurred
Adequate cardiac, renal, pulmonary, and hepatic function
Patient must have a life expectancy of at least 2 months
Females of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
Females of childbearing potential and males should agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation

Exclusion Criteria:

Recipients of prior allogeneic hematopoietic stem cell transplant (HSCT) with active acute or chronic GVHD
Patients with history of Down's syndrome, Fanconi anemia or other known marrow failure condition
Patients currently receiving other investigational drugs are not eligible
Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol with the exception of intrathecal chemotherapy; this includes the tyrosine kinase inhibitor sorafenib which must not be initiated until patient demonstrates count recovery
Patients with a systemic fungal, bacterial, viral, or other infection not controlled despite appropriate antibiotics or other treatment; uncontrolled systemic infections require infectious disease consultation for verification
Patients who are platelet refractory prior to initiation of protocol therapy
Pregnant or lactating patients
Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Emory University/Winship Cancer Institute	Atlanta	Georgia	United States	30322
2	Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium	Seattle	Washington	United States	98109